PMC:7344504 / 12084-13299 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T22","span":{"begin":0,"end":5},"obj":"Body_part"},{"id":"T23","span":{"begin":214,"end":219},"obj":"Body_part"},{"id":"T24","span":{"begin":320,"end":325},"obj":"Body_part"},{"id":"T25","span":{"begin":577,"end":582},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T15","span":{"begin":0,"end":5},"obj":"Body_part"},{"id":"T16","span":{"begin":214,"end":219},"obj":"Body_part"},{"id":"T17","span":{"begin":320,"end":325},"obj":"Body_part"},{"id":"T18","span":{"begin":577,"end":582},"obj":"Body_part"}],"attributes":[{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"328","span":{"begin":105,"end":113},"obj":"Species"},{"id":"329","span":{"begin":180,"end":188},"obj":"Species"},{"id":"330","span":{"begin":637,"end":644},"obj":"Species"},{"id":"331","span":{"begin":1044,"end":1052},"obj":"Species"},{"id":"332","span":{"begin":455,"end":466},"obj":"Species"},{"id":"333","span":{"begin":6,"end":19},"obj":"Chemical"},{"id":"334","span":{"begin":220,"end":233},"obj":"Chemical"},{"id":"335","span":{"begin":326,"end":339},"obj":"Chemical"},{"id":"336","span":{"begin":436,"end":446},"obj":"Chemical"},{"id":"337","span":{"begin":583,"end":593},"obj":"Chemical"},{"id":"338","span":{"begin":719,"end":729},"obj":"Chemical"},{"id":"339","span":{"begin":1075,"end":1085},"obj":"Chemical"},{"id":"340","span":{"begin":136,"end":158},"obj":"Disease"},{"id":"341","span":{"begin":543,"end":551},"obj":"Disease"},{"id":"342","span":{"begin":692,"end":707},"obj":"Disease"},{"id":"343","span":{"begin":895,"end":918},"obj":"Disease"},{"id":"344","span":{"begin":1003,"end":1025},"obj":"Disease"},{"id":"345","span":{"begin":1029,"end":1043},"obj":"Disease"}],"attributes":[{"id":"A328","pred":"tao:has_database_id","subj":"328","obj":"Tax:9606"},{"id":"A329","pred":"tao:has_database_id","subj":"329","obj":"Tax:9606"},{"id":"A330","pred":"tao:has_database_id","subj":"330","obj":"Tax:9606"},{"id":"A331","pred":"tao:has_database_id","subj":"331","obj":"Tax:9606"},{"id":"A332","pred":"tao:has_database_id","subj":"332","obj":"Tax:746128"},{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"MESH:C012990"},{"id":"A334","pred":"tao:has_database_id","subj":"334","obj":"MESH:C012990"},{"id":"A335","pred":"tao:has_database_id","subj":"335","obj":"MESH:C012990"},{"id":"A340","pred":"tao:has_database_id","subj":"340","obj":"MESH:D055744"},{"id":"A341","pred":"tao:has_database_id","subj":"341","obj":"MESH:C000657245"},{"id":"A342","pred":"tao:has_database_id","subj":"342","obj":"MESH:D000072742"},{"id":"A343","pred":"tao:has_database_id","subj":"343","obj":"MESH:D000072742"},{"id":"A344","pred":"tao:has_database_id","subj":"344","obj":"MESH:D055744"},{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"MESH:D016638"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T44","span":{"begin":136,"end":158},"obj":"Disease"},{"id":"T45","span":{"begin":145,"end":158},"obj":"Disease"},{"id":"T46","span":{"begin":543,"end":551},"obj":"Disease"},{"id":"T47","span":{"begin":1003,"end":1025},"obj":"Disease"},{"id":"T48","span":{"begin":1012,"end":1025},"obj":"Disease"}],"attributes":[{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T83","span":{"begin":20,"end":27},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T84","span":{"begin":28,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T85","span":{"begin":49,"end":50},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T86","span":{"begin":260,"end":263},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T87","span":{"begin":279,"end":281},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T88","span":{"begin":489,"end":495},"obj":"http://purl.obolibrary.org/obo/OBI_0000968"},{"id":"T89","span":{"begin":664,"end":665},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T90","span":{"begin":730,"end":737},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T91","span":{"begin":741,"end":742},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T92","span":{"begin":764,"end":767},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T93","span":{"begin":875,"end":887},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T94","span":{"begin":963,"end":964},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T95","span":{"begin":1211,"end":1213},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T93","span":{"begin":6,"end":19},"obj":"Chemical"},{"id":"T94","span":{"begin":220,"end":233},"obj":"Chemical"},{"id":"T95","span":{"begin":326,"end":339},"obj":"Chemical"},{"id":"T96","span":{"begin":440,"end":446},"obj":"Chemical"},{"id":"T97","span":{"begin":497,"end":500},"obj":"Chemical"},{"id":"T98","span":{"begin":536,"end":539},"obj":"Chemical"},{"id":"T100","span":{"begin":587,"end":593},"obj":"Chemical"},{"id":"T101","span":{"begin":723,"end":729},"obj":"Chemical"},{"id":"T102","span":{"begin":1071,"end":1074},"obj":"Chemical"},{"id":"T103","span":{"begin":1079,"end":1085},"obj":"Chemical"}],"attributes":[{"id":"A93","pred":"chebi_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A95","pred":"chebi_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A96","pred":"chebi_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/CHEBI_37163"},{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_73571"},{"id":"A98","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A99","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_37163"},{"id":"A101","pred":"chebi_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/CHEBI_37163"},{"id":"A102","pred":"chebi_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/CHEBI_64198"},{"id":"A103","pred":"chebi_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/CHEBI_37163"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T3","span":{"begin":6,"end":19},"obj":"GlycoEpitope"},{"id":"T4","span":{"begin":220,"end":233},"obj":"GlycoEpitope"},{"id":"T5","span":{"begin":326,"end":339},"obj":"GlycoEpitope"}],"attributes":[{"id":"A3","pred":"glyco_epitope_db_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0510"},{"id":"A4","pred":"glyco_epitope_db_id","subj":"T4","obj":"http://www.glycoepitope.jp/epitopes/EP0510"},{"id":"A5","pred":"glyco_epitope_db_id","subj":"T5","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T96","span":{"begin":0,"end":167},"obj":"Sentence"},{"id":"T97","span":{"begin":168,"end":423},"obj":"Sentence"},{"id":"T98","span":{"begin":424,"end":576},"obj":"Sentence"},{"id":"T99","span":{"begin":577,"end":671},"obj":"Sentence"},{"id":"T100","span":{"begin":672,"end":919},"obj":"Sentence"},{"id":"T101","span":{"begin":920,"end":1070},"obj":"Sentence"},{"id":"T102","span":{"begin":1071,"end":1215},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T20","span":{"begin":536,"end":539},"obj":"Phenotype"}],"attributes":[{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}

{"project":"2_test","denotations":[{"id":"32517166-17885264-60114400","span":{"begin":160,"end":162},"obj":"17885264"},{"id":"32517166-11015433-60114401","span":{"begin":163,"end":165},"obj":"11015433"},{"id":"32517166-17885264-60114402","span":{"begin":279,"end":281},"obj":"17885264"},{"id":"32517166-32396381-60114403","span":{"begin":416,"end":417},"obj":"32396381"},{"id":"32517166-32339350-60114404","span":{"begin":420,"end":421},"obj":"32339350"},{"id":"32517166-31361683-60114405","span":{"begin":572,"end":574},"obj":"31361683"},{"id":"32517166-28384600-60114406","span":{"begin":836,"end":838},"obj":"28384600"},{"id":"32517166-20825441-60114407","span":{"begin":1054,"end":1056},"obj":"20825441"},{"id":"32517166-21811868-60114408","span":{"begin":1057,"end":1059},"obj":"21811868"},{"id":"32517166-30015290-60114409","span":{"begin":1060,"end":1062},"obj":"30015290"},{"id":"32517166-21880959-60114410","span":{"begin":1063,"end":1065},"obj":"21880959"},{"id":"32517166-27475024-60114411","span":{"begin":1066,"end":1068},"obj":"27475024"}],"text":"Serum galactomannan testing has been shown to be a fairly sensitive diagnostic tool (70%) in neutropenic patients with pathology-proven invasive aspergillosis [27,28]. However, in patients who are non-neutropenic, serum galactomannan sensitivity of around 25% has been reported [27], which may explain the low number of serum galactomannan positive findings in recently published case reports [6,7] and case series [3,4,5]. The role of β-d-glucan and the Aspergillus-specific lateral flow device (LFD) as an adjunct to the diagnosis of IPA in COVID-19 is not yet clear [2,23]. Serum β-d-glucan was persistently strongly positive in this patient over the course of a week. The specificity for invasive fungal disease of β-d-glucan testing in a mixed ICU population has been shown to be high (86%), with two consecutive positive results [29] compared to those with only fungal colonization and no invasive fungal disease. In addition, multiple other studies report a good sensitivity for the diagnosis of invasive aspergillosis in critically ill patients [30,31,32,33,34]. BAL β-d-glucan in the ICU setting is, however, not recommended, due to its poor specificity and confounders causing false positive results [35]."}